Lipid Nanoparticle-Based Systems for Delivery of Biomacromolecule Therapeutics

Delivery Technologies for Biopharmaceuticals: Peptides, Proteins, Nucleic Acids and Vaccines

Volumn , Issue , 2009, Pages 129-148

  Martins, Susana ^a   Ferreira, Domingos C ^a   Souto, Eliana B ^b,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^c UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

Author keywords

Administration, delivery and targeting; Biopharmaceutical applications; Bovine serum albumin (BSA) crystals; Commercial feasibility desired characteristic of novel delivery system; Delivery technologies for biopharmaceuticals; Gene therapy promising strategy in cancer therapy; Lipid nanoparticle based systems for biomacromolecule therapeutic delivery; Novel formulation development for NDEs; Solid lipid nanoparticles (SLNs) new class of drug carrier

Indexed keywords

EID: 84864131420     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470688397.ch7     Document Type: Chapter

References (118)

1. Devalapally, H., Chakilam, A. and Amiji, M.M. (2007) Role of nanotechnology in pharmaceutical product development. J. Pharm. Sci., 96, 2547-2565.
2. Almeida, A.J. and Souto, E. (2007) Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev., 59, 478-490.
3. Caliceti, P., Brossa, A., Salmaso, S. et al. (2006) Preparation of protein loaded solid lipid nano-particles by compressed fluid process. Proc. Intern. Symp. Control. Rel. Bioact. Mater., 33, 383.
4. Asasutjarit, R., Lorenzen, S.I., Sirivichayakul, S. et al. (2007) Effect of solid lipid nanoparticles formulation compositions on their size, zeta potential and potential for in vitro pHIS-HIV-hugag transfection. Pharm. Res., 24, 1098-1107.
5. Brioschi, A., Zenga, F., Zara, G.P. et al. (2007) Solid lipid nanoparticles: could they help to improve the efficacy of pharmacologic treatments for brain tumors? Neurol. Res., 29, 324-330.
6. Bondi, M.L., Azzolina, A., Craparo, E.F. et al. (2007) Novel cationic solid-lipid nanoparticles as non-viral vectors for gene delivery. J. Drug Target, 15, 295-301.
7. Choi, M.J., Kim, J.H. and Maibach, H.I. (2006) Topical DNA vaccination with DNA/Lipid based complex. Curr. Drug Deliv., 3, 37-45.
8. Choi, S.H., Jin, S.E., Lee, M.K. et al. (2008) Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells. Eur. J. Pharm. Biopharm., 68, 545-554.
9. Pedersen, N., Hansen, S., Heydenreich, A.V. et al. (2006) Solid lipid nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands. Eur. J. Pharm. Biopharm., 62, 155-162.
10. del Pozo-Rodriguez, A., Delgado, D., Solinis, M.A. et al. (2007) Solid lipid nanoparticles: formulation factors affecting cell transfection capacity. Int. J. Pharm., 339, 261-268.
11. Montana, G., Bondi, M.L., Carrotta, R. et al. (2007) Employment of cationic solid-lipid nanoparticles as RNA carriers. Bioconjug. Chem., 18, 302-308.
12. Kim, H.R., Kim, I.K., Bae, K.H. et al. (2008) Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA. Mol. Pharm., 5 (4), 622-631.
13. Mehnert, W. and Mader, K. (2001) Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev., 47, 165-196.
14. Muller, R.H. and Keck, C.M. (2004) Drug delivery to the brain-realization by novel drug carriers. J. Nanosci. Nanotechnol., 4, 471-483.
15. Muller, R.H. and Keck, C.M. (2004) Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J. Biotechnol., 113, 151-170.
16. Muller, R.H., Mader, K. and Gohla, S. (2000) Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur. J. Pharm. Biopharm., 50, 161-177.
17. Souto, E.B. and Müller, R.H. (2007) Lipid nanoparticles (SLN and NLC) for drug delivery, in Nanoparticles for Pharmaceutical Applications, (eds A.J. Domb, Y. Tabata, M.N.V. Ravi Kumar and S. Farber), American Scientific Publishers, Los Angeles, California, pp. 103-122.
18. Uner, M. (2006) Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Pharmazie, 61, 375-386.
19. Wissing, S.A., Kayser, O. and Muller, R.H. (2004) Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev., 56, 1257-1272.
20. Smith, A. and Hunneyball, I.M. (1986) Evaluation of polylactid as a biodegradabledrug delivery system for parenteral administration. Int. J. Pharm., 30, 215-230.
21. Lasic, D.D. (1998) Novel applications of liposomes. Tibetech, 16, 307-321.
22. Dingler, A. and Gohla, S. (2002) Production of solid lipid nanoparticles (SLN): scaling up feasibilities. J. Microencapsul., 19, 11-16.
23. Muller, R.H., Ruhl, D., Runge, S. et al. (1997) Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm. Res., 14, 458-462.
24. Muller, R.H., Maassen, S., Weyhers, H. and Mehnert, W. (1996) Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J. Drug Target, 4, 161-170.
25. Müller, R.H. and Lucks, J.S. (1996) Arzneistoffträ ger aus festen Lipidteilchen-Feste Lipid Nanosphä ren (SLN). European Patent 0605497: Germany.
26. Souto, E.B., Petersen, R.D. and Müller, R.H. (2008) Lipid nanoparticles with solid matrix for dermal delivery, in Modified Release Drug Delivery Technology, (eds M.J. Rathbone, J. Hadgraft, M.S. Roberts and M. Lane), Marcel Dekker Inc., New York, Basel, Hong Kong, pp. 357-379.
27. Schubert, M.A. and Muller-Goymann, C.C. (2005) Characterisation of surface-modified solid lipid nanoparticles (SLN): influence of lecithin and nonionic emulsifier. Eur. J. Pharm. Biopharm., 61, 77-86.
28. Dubes, A., Parrot-Lopez, H., Abdelwahed, W. et al. (2003) Scanning electron microscopy and atomic force microscopy imaging of solid lipid nanoparticles derived from amphiphilic cyclodextrins. Eur. J. Pharm. Biopharm., 55, 279-282.
29. Shahgaldian, P., Da Silva, E., Coleman, A.W. et al. (2003) Para-acyl-calix-arene based solid lipid nanoparticles (SLNs): a detailed study of preparation and stability parameters. Int. J. Pharm., 253, 23-38.
30. Müller, R.H., Mä der, K., Lippacher, A. and Jenning, V. (1998) Fest-flü ssig (halbfeste) Lipidpartikel und Verfahren zur Herstellung hochkonzentrierter Lipidpartikeldispersionen. In PCT application PCT/EP00/04565.
31. Gasco, M.R. (1993) Method for producing solid lipid microspheres having a narrow size distribution. US Patent 5 250 236: Italy.
32. Heurtault, B., Saulnier, P., Pech, B. et al. (2002) A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm. Res., 19, 875-880.
33. Sjostrom, B.B.B. (1992) Preparation of submicron drug particles in lecithin-stabilized o/w emulsions I. Model studies of the precipitation of cholesteryl acetate. Int. J. Pharm., 88, 53-62.
34. Charcosset, C., El-Harati, A. and Fessi, H. (2005) Preparation of solid lipid nanoparticles using a membrane contactor. J. Control. Release, 108, 112-120.
35. Charcosset, C. and Fessi, H. (2005) A new process for drug loaded nanocapsules preparation using a membrane contactor. Drug Dev. Ind. Pharm., 31, 987-992.
36. Sarmento, B., Martins, S., Ferreira, D. and Souto, E.B. (2007) Oral insulin delivery by means of solid lipid nanoparticles. Int. J. Nanomed., 2, 743-749.
37. Siekmann, B. and Westesen, K. (1996) Investigations on solid lipid nanoparticles prepared by precipitation in o/w emulsions. Eur. J. Pharm. Biopharm., 43, 104-109.
38. Huang, G., Zhang, N., Bi, X. and Dou, M. (2008) Solid lipid nanoparticles of temozolomide: potential reduction of cardial and nephric toxicity. Int. J. Pharm., 355, 314-320.
39. Liu, J., Zhu, J., Du, Z. and Qin, B. (2005) Preparation and pharmacokinetic evaluation of Tashinone IIA solid lipid nanoparticles. Drug Dev. Ind. Pharm., 31, 551-556.
40. Trotta, M., Debernardi, F. and Caputo, O. (2003) Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. Int. J. Pharm., 257, 153-160.
41. Chattopadhyay, P., Shekunov, B.Y., Yim, D. et al. (2007) Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. Adv. Drug Deliv. Rev., 59, 444-453.
42. Jovanovic, N., Bouchard, A., Hofland, G.W. et al. (2004) Stabilization of proteins in dry powder formulations using supercritical fluid technology. Pharm. Res., 21, 1955-1969.
43. Dos Santos, R., Richard, I., Pech, J. et al. (2002) Microencapsulation of protein particles within lipids using a novel supercritical fluid process. Int. J. Pharm., 242, 69-78.
44. Dos Santos, R., Richard, I., Thies, J. et al. (2003) A supercritical fluid-based coating technology. 3: preparation and characterization of bovine serum albumin particles coated with lipids. J. Microencapsul., 20, 110-128.
45. Olbrich, C., Gessner, A., Kayser, O. and Muller, R.H. (2002) Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate . J. Drug Target, 10, 387-396.
46. Olbrich, C., Gessner, A., Schroder, W. et al. (2004) Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene-cytotoxicity testing and mouse serum adsorption. J. Control. Release, 96, 425-435.
47. Florence, A.T., Hillery, A.M., Hussain, N. and Jani, P.U. (1995) Factors affecting the oral uptake and translocation of polystyrene nanoparticles: histological and analytical evidence. J. Drug Target, 3, 65-70.
48. Bargoni, A., Cavalli, R., Caputo, O. et al. (1998) Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm. Res., 15, 745-750.
49. Garcia-Fuentes, M., Prego, C., Torres, D. and Alonso, M.J. (2005) A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. Eur. J. Pharm. Sci., 25, 133-143.
50. Zhang, N., Ping, Q., Huang, G. et al. (2006) Transport characteristics of wheat germ agglutinin-modified insulin-liposomes and solid lipid nanoparticles in a perfused rat intestinal model. J. Nanosci. Nanotechnol., 6, 2959-2966.
51. Zhang, N., Ping, Q., Huang, G. et al. (2006) Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int. J. Pharm., 327, 153-159.
52. Saraf, S., Mishra, D., Asthana, A. et al. (2006) Lipid microparticles for mucosal immunization against hepatitis B. Vaccine, 24, 45-56.
53. Videira, M.A., Botelho, M.F., Santos, A.C. et al. (2002) Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J. Drug Target, 10, 607-613.
54. Videira, M.A., Gano, L., Santos, C. et al. (2006) Lymphatic uptake of lipid nanoparticles following endotracheal administration. J. Microencapsul., 23, 855-862.
55. Cavalli, R., Gasco, M.R., Chetoni, P. et al. (2002) Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int. J. Pharm., 238, 241-245.
56. Sznitowska, M., Gajewska, M., Janicki, S. et al. (2001) Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. Eur. J. Pharm. Biopharm., 52, 159-163.
57. Wong, H.L., Bendayan, R., Rauth, A.M. et al. (2007) Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev., 59, 491-504.
58. Wong, H.L., Bendayan, R., Rauth, A.M. and Wu, X.Y. (2004) Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J. Pharm. Sci., 93, 1993-2008.
59. Muller, R.H., Runge, S., Ravelli, V. et al. (2006) Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int. J. Pharm., 317, 82-89.
60. Muller, R.H., Runge, S.A., Ravelli, V. et al. (2008) Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation . Eur. J. Pharm. Biopharm., 68, 535-544.
61. Varia, J.K., Dodiya, S.S. and Sawant, K.K. (2008) Cyclosporine a loaded solid lipid nanoparticles: optimization of formulation, process variable and characterization. Curr. Drug Deliv., 5, 64-69.
62. Zhang, Q., Yie, G., Li, Y. et al. (2000) Studies on the cyclosporin A loaded stearic acid nanoparticles . Int. J. Pharm., 200, 153-159.
63. Ugazio, E., Cavalli, R. and Gasco, M.R. (2002) Incorporation of cyclosporin A in solid lipid nanoparticles (SLN). Int. J. Pharm., 241, 341-344.
64. Ewesuedo, R.B. and Ratain, M.J. (2003) Principles of cancer chemotherapy, in Oncologic Therapeutics (eds E.E. Vokes and HMG), Springer, New York, pp. 19-66.
65. Wong, H.L., Bendayan, R., Rauth, A.M. et al. (2007) Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev., 59, 491-504.
66. Date, A.A., Joshi, M.D. and Patravale, V.B. (2007) Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv. Drug Deliv. Rev., 59, 505-521.
67. Fundaro, A., Cavalli, R., Bargoni, A. et al. (2000) Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol. Res., 42, 337-343.
68. Cavalli, R., Bocca, C., Miglietta, A. et al. (1999) Albumin adsorption on stealth and non-stealth solid lipid nanoparticles. STP Pharma. Sci., 9, 183-189.
69. Olbrich, C., Bakowsky, U., Lehr, C.M. et al. (2001) Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J. Control. Release, 77, 345-355.
70. Müller, R.H. and Tabatt, K. (2002) ransoPlex-novel transfection agents based on solid lipid nanoparticles (SLN). In Annual Meeting of AAPS, Toronto, Canada, pp. 10-14.
71. Heiati, H., Tawashi, R. and Phillips, N.C. (1998) Solid lipid nanoparticles as drug carriers: II. Plasma stability and biodistribution of solid lipid nanoparticles containing the lipophilic prodrug 3 ′-azido-3 ′-deoxythymidine palmitate in mice. Int. J. Pharm., 174, 71-80.
72. Yang, S., Zhu, J., Lu, Y. et al. (1999) Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm. Res., 16, 751-757.
73. Zara, G.P., Bargoni, A., Cavalli, R. et al. (2002) Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J. Pharm. Sci., 91, 1324-1333.
74. Goppert, T.M. and Muller, R.H. (2005) Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. J. Drug Target, 13, 179-187.
75. Goppert, T.M. and Muller, R.H. (2005) Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting. Int. J. Pharm., 302, 172-186.
76. Scholer, N., Hahn, H., Muller, R.H. and Liesenfeld, O. (2002) Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int. J. Pharm., 231, 167-176.
77. Scholer, N., Olbrich, C., Tabatt, K. et al. (2001) Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages. Int. J. Pharm., 221, 57-67.
78. Scholer, N., Zimmermann, E., Katzfey, U. et al. (2000) Preserved solid lipid nanoparticles (SLN) at low concentrations do cause neither direct nor indirect cytotoxic effects in peritoneal macrophages. Int. J. Pharm., 196, 235-239.
79. Koziara, J., Oh, J., Akers, W. et al. (2005) Blood compatibility of cetyl alcohol/polysorbate-based nanoparticles. Pharm. Res., 22, 1821-1828.
80. Olbrich, C. and Muller, R.H. (1999) Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int. J. Pharm., 180, 31-39.
81. Wissing, S.A., Kayser, O. and Muller, R.H. (2004) Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev., 56, 1257-1272.
82. Olbrich, C., Scholer, N., Tabatt, K. et al. (2004) Cytotoxicity studies of Dynasan 114 solid lipid nanoparticles (SLN) on RAW 264.7 macrophages-impact of phagocytosis on viability and cytokine production. J. Pharm. Pharmacol., 56, 883-891.
83. Liu, J., Gong, T., Fu, H. et al. (2008) Solid lipid nanoparticles for pulmonary delivery of insulin. Int. J. Pharm., 356, 333-344.
84. Battaglia, L., Trotta, M., Gallarate, M. et al. (2007) Solid lipid nanoparticles formed by solvent-in-water emulsion-diffusion technique: development and influence on insulin stability. J. Microencapsul., 24, 660-672.
85. Liu, J., Gong, T., Wang, C. et al. (2007) Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization. Int. J. Pharm., 340, 153-162.
86. Garcia-Fuentes, M., Torres, D. and Alonso, M.J. (2005) New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin. Int. J. Pharm., 296, 122-132.
87. Martins, S., Silva, A.C., Ferreira, D. and Souto, E.B. (2009) Improving oral absorption of Samon calcitonin by trimyristin lipid nanoparticles. J. Biomed. Nanotechnol., 5, 76-83.
88. Garcia-Fuentes, M., Alonso, M.J. and Torres, D. (2005) Design and characterization of a new drug nanocarrier made from solid-liquid lipid mixtures. J. Colloid Interface Sci., 285, 590-598.
89. Goppert, T.M. and Muller, R.H. (2005) Protein adsorption patterns on poloxamer-and poloxamine-stabilized solid lipid nanoparticles (SLN). Eur. J. Pharm. Biopharm., 60, 361-372.
90. Scanlon, K.J. (2004) Anti-genes: siRNA, ribozymes and antisense. Curr. Pharm. Biotechnol., 5, 415-420.
91. Li, B.J., Tang, Q., Cheng, D. et al. (2005) Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat. Med., 11, 944-951.
92. Alonso, M.J. (2004) Nanomedicines for overcoming biological barriers. Biomed. Pharmacother., 58, 168-172.
93. Matzke, M.A. and Birchler, J.A. (2005) RNAi-mediated pathways in the nucleus. Nat. Rev. Genet, 6, 24-35.
94. Li, W., Nicol, F. and Szoka, F.C. Jr. (2004) GALA: a designed synthetic pH-responsive amphipathic peptide with applications in drug and gene delivery. Adv. Drug Deliv. Rev., 56, 967-985.
95. Cavallaro, G., Campisi, M., Licciardi, M. et al. (2006) Reversibly stable thiopolyplexes for intracellular delivery of genes. J. Control. Release, 115, 322-334.
96. Licciardi, M., Campisi, M., Cavallaro, G. et al. (2006) Synthesis and characterization of polyaminoacidic polycations for gene delivery. Biomaterials, 27, 2066-2075.
97. Tabatt, K., Kneuer, C., Sameti, M. et al. (2004) Transfection with different colloidal systems: comparison of solid lipid nanoparticles and liposomes. J. Control. Release, 97, 321-332.
98. Tabatt, K., Sameti, M., Olbrich, C. et al. (2004) Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticle-mediated gene transfer. Eur. J. Pharm. Biopharm., 57, 155-162.
99. Rudolph, C., Schillinger, U., Ortiz, A. et al. (2004) Application of novel solid lipid nanoparticle (SLN)-gene vector formulations based on a dimeric HIV-1 TAT-peptide in vitro and in vivo. Pharm. Res., 21, 1662-1669.
100. Tokunaga, M., Hazemoto, N. and Yotsuyanagi, T. (2004) Effect of oligopeptides on gene expression: comparison of DNA/peptide and DNA/peptide/liposome complexes. Int. J. Pharm., 269, 71-80.
101. Hyndman, L., Lemoine, J.L., Huang, L. et al. (2004) HIV-1 Tat protein transduction domain peptide facilitates gene transfer in combination with cationic liposomes. J. Control. Release, 99, 435-444.
102. El-Aneed, A. (2004) Current strategies in cancer gene therapy. Eur. J. Pharmacol., 498, 1-8.
103. El-Aneed, A. (2004) An overview of current delivery systems in cancer gene therapy. J. Control. Release, 94, 1-14.
104. Freitas, C. and Muller, R.H. (1999) Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur. J. Pharm. Biopharm., 47, 125-132.
105. Faneca, H., Simoes, S. and de Lima, M.C. (2002) Evaluation of lipid-based reagents to mediate intracellular gene delivery. Biochim. Biophys. Acta, 1567, 23-33.
106. Sakurai, F., Inoue, R., Nishino, Y. et al. (2000) Effect of DNA/liposome mixing ratio on the physicochemical characteristics, cellular uptake and intracellular trafficking of plasmid DNA/cationic liposome complexes and subsequent gene expression. J. Control. Release, 66, 255-269.
107. Remaut, K., Sanders, N.N., Fayazpour, F. et al. (2006) Influence of plasmid DNA topology on the transfection properties of DOTAP/DOPE lipoplexes. J. Control. Release, 115, 335-343.
108. Elouahabi, A. and Ruysschaert, J.M. (2005) Formation and intracellular trafficking of lipoplexes and polyplexes. Mol. Ther., 11, 336-347.
109. Rejman, J., Bragonzi, A. and Conese, M. (2005) Role of clathrin-and caveolae-mediated endocytosis in gene transfer mediated by lipo-and polyplexes. Mol. Ther., 12, 468-474.
110. Elouahabi, A., Thiry, M., Pector, V. et al. (2003) Calorimetry of cationic liposome-DNA complex and intracellular visualization of the complexes. Methods Enzymol., 373, 313-332.
111. Han, S., Mahato, R.I., Sung, Y.K. and Kim, S.W. (2000) Development of biomaterials for gene therapy. Mol. Ther., 2, 302-317.
112. Edelstein, M.L., Abedi, M.R. and Wixon, J. (2007) Gene therapy clinical trials worldwide to 2007-an update. J. Gene Med., 9, 833-842.
113. Calvo, P., Alonso, M.J., Vila-Jato, J.L. and Robinson, J.R. (1996) Improved ocular bioavailability of indomethacin by novel ocular drug carriers. J. Pharm. Pharmacol., 48, 1147-1152.
114. Weyenberg, W., Filev, P., Van den Plas, D. et al. (2007) Cytotoxicity of submicron emulsions and solid lipid nanoparticles for dermal application. Int. J. Pharm., 337, 291-298.
115. Parker, L.P., Wolf, J.K. and Price, J.E. (2000) Adenoviral-mediated gene therapy with Ad5CMVp53 and Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines. Ann. Clin. Lab. Sci., 30, 395-405.
116. Agger, E.M., Cassidy, J.P., Brady, J. et al. (2008) Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection. Immunology, 124, 175-185.
117. Bergers, J.J., ten Hagen, T.L., van Etten, E.W. and Bakker-Woudenberg, I.A. (1995) Liposomes as delivery systems in the prevention and treatment of infectious diseases. Pharm. World. Sci., 17, 1-11.
118. Gregoriadis, G. (1999) DNA vaccines: a role for liposomes. Curr. Opin. Mol. Ther., 1, 39-42.